Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFevertree Regulatory News (FEVR)

Share Price Information for Fevertree (FEVR)

Share Price is delayed by 15 minutes
Get Live Data
759.00    8.00 (1.07%)
Bid:
759.50
Ask:
761.50
Spread: 2.00 (0.263%)
Market Cap: £864.81m
FEVR Live PriceLast checked at - London Stock Exchange

Intraday Fevertree Share Chart

AGM STATEMENT & COVID-19 UPDATE

4 Jun 2020 07:00

RNS Number : 8775O
Fevertree Drinks PLC
04 June 2020
 

June 4th, 2020

 

Fever-Tree Drinks plc

AGM STATEMENT & COVID-19 UPDATE

 

Fever-Tree, the world's leading supplier of premium carbonated mixers, is holding its Annual General Meeting ("AGM") today at 11.30am BST.

At the AGM, Bill Ronald, Chairman of Fever-Tree, will make the following statement:

"As highlighted at the Group's preliminary results in April, although we have been impacted by the COVID-19 crisis, we are well positioned to manage our way through the current situation. We have a fantastic team across the globe who have been working incredibly hard alongside our key customers, suppliers and distribution partners. Our asset light business model continues to support our secure financial position with a FY19 net cash position of £128 million and we benefit from a strong brand portfolio with well-balanced revenue streams across regions, channels and customers.

While the On-Trade remains fully or partially closed across many of our regions, the Group's performance across the Off-Trade continues to be very encouraging. Management remain focused on delivering our long-term strategy and we are confident the Group will be well placed once the current period of uncertainty ends."

 

COVID-19 Update

UK

On-Trade sales typically represent 50% of UK revenue and continue to be severely impacted by the lockdown. Conversely, our Off-Trade performance has been strong. Sales in the first full month of lockdown were up 24%1 year-on-year and we have seen continued positive momentum since, reflecting increased at home consumption during the period. The core tonic range has performed particularly well, and there has also been notable growth in the convenience channel as consumers increasingly supplement or substitute their trips to large grocery stores.

US

The US market is naturally weighted to the Off-Trade, which typically contributes 70% to the Group's US revenue. Since the start of lockdown, while On-Trade sales have been severely impacted, Off-Trade sales have grown extremely strongly. Nielsen data, which covers just under half of Fever-Tree's Off-Trade sales in the US, reported 98%2 growth year-on-year for the four weeks to 18th April and 96%2 in the four weeks to the 16th May. Whilst this performance reflects the benefit of incremental distribution that was secured over the course of H2 2019, along with increased at-home consumption during lockdown, it also highlights the growing strength of the Fever-Tree brand, supported by the continued trend towards premium, long drinks. In addition, the Group's US pricing and format optimisation has been very well received by distributors and retailers, with implementation beginning to be seen on-shelf between March and June 2020.

Europe

The impacts from COVID-19 have varied across countries within Europe. While Northern Europe is naturally weighted to the Off-Trade and has therefore been more robust, Southern Europe is more reliant on the On-Trade, causing it to be more significantly affected. However, we remain confident in building our momentum in this region over the medium and long-term as premiumisation continues to gain traction. Fever-Tree is the only premium brand with scale across the entire region, with a category leading position in many markets.

ROW

While On-Trade challenges have also been evident across the ROW, we are delivering strong Off-Trade sales and continued distribution gains, most notably in Australia and Canada.

Operations and Employees

Our unique asset light, outsourced business model has provided the Group with the flexibility to react to the challenges that COVID-19 presents. We continue to work closely with our suppliers, partners and customers across our supply chain and although there have been some challenges, we continue to maintain continuity of production and supply, as well as the quality of our products.

Fever-Tree continues to support and provide job certainty to all our employees, as well as supporting key workers and the communities in which we operate. We have not furloughed any of our employees regardless of their role and the team remains focused on identifying opportunities that will put us in a strong position as we look to 2021 and beyond. We are also continuing to work closely with our On-Trade partners across our regions, offering support and assistance where relevant as they prepare to re-open.

FY20 outlook

Given the uncertainty and dynamic nature of the situation, it continues to be hard to predict how sales will evolve both during and as we emerge from the lockdown period. The easing of restrictions and the pace at which the On-Trade re-opens will vary between regions, but it is becoming increasingly likely that this process will be gradual and cautious, with social distancing measures remaining in place for some time.

As highlighted at the Group's preliminary results in April, COVID-19 will have a material impact on FY20 trading, with headwinds on gross margin due to changes in channel and territory mix. However, we remain committed to continuing to invest through this period of uncertainty as opportunities arise, particularly in marketing, enabled by the Group's strong balance sheet and conviction in our ability to deliver long-term sustainable growth.

For more information please contact:

Investor queries

Ann Hyams, Director of Investor Relations I ann.hyams@fever-tree.com I +44 (0)7435 828 138

Nominated Advisor and Joint Broker - Numis Securities

Garry Levin I Matt Lewis I Hugo Rubinstein I +44 (0)20 7260 1000

Joint Broker - Investec Bank plc

David Flin I Alex Wright I David Anderson I +44 (0)20 7597 5970

 

Media queries

Oliver Winters, Director of Communications I oliver.winters@fever-tree.com I +44 (0)770 332 9024

Brunswick Group I fevertree@brunswickgroup.com I +44 (0) 207 404 5959

 

 

1IRI 4 weeks ending 19 April 2020; 2Nielsen 4 weeks ending 18th April & 16th May

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
AGMUOSVRRNUNRAR
Date   Source Headline
18th Feb 20257:00 amRNSTransaction in Own Shares
17th Feb 20257:00 amRNSCommencement of share buyback programme
10th Feb 20251:35 pmRNSHolding(s) in Company
7th Feb 20254:35 pmRNSHolding(s) in Company
7th Feb 20254:07 pmRNSHolding(s) in Company
7th Feb 20254:05 pmRNSHolding(s) in Company - correction
6th Feb 202511:39 amRNSHolding(s) in Company
5th Feb 20255:39 pmRNSHolding(s) in Company
5th Feb 20257:00 amRNSCompletion of Share Issuance to Molson Coors
3rd Feb 202512:20 pmRNSStandard form for notification of major holdings
30th Jan 20253:01 pmRNSDirector/PDMR Shareholding
30th Jan 20257:02 amRNSUS Strategic Partnership with Molson Coors
20th Jan 20257:00 amRNSAppointment Of Corporate Broker
6th Jan 20252:15 pmRNSStandard form for notification of major holdings
2nd Dec 202411:47 amRNSStandard form for notification of major holdings
2nd Dec 20247:00 amRNSBlock Listing Return
2nd Dec 20247:00 amRNSTotal Voting Rights
28th Nov 20245:12 pmRNSStandard form for notification of major holdings
18th Sep 20242:42 pmRNSStandard form for notification of major holdings
12th Sep 20247:00 amRNSFY24 Interim Results to 30 June 2024
2nd Sep 20247:00 amRNSTotal Voting Rights
1st Aug 20247:00 amRNSTotal Voting Rights
1st Jul 20247:00 amRNSTotal Voting Rights
6th Jun 20241:29 pmRNSResult of AGM
6th Jun 20247:00 amRNSAGM Trading Statement
3rd Jun 20247:00 amRNSBlock Listing Return
3rd Jun 20247:00 amRNSTotal Voting Rights
9th May 20247:00 amRNSNotice of AGM
7th May 20247:00 amRNSGrant of Options
1st May 20247:00 amRNSTotal Voting Rights
27th Mar 20247:00 amRNSHolding(s) in Company
26th Mar 20247:00 amRNSFY23 Preliminary Results to 31 December 2023
25th Jan 202412:05 pmRNSDirector/PDMR Shareholding
25th Jan 20247:00 amRNSFY23 pre-close trading update
18th Jan 20242:30 pmRNSBlock Admission Application
18th Jan 20242:30 pmRNSAdmission Application
14th Dec 20232:33 pmRNSDirectorate Change
1st Dec 20237:00 amRNSBlock Listing Return
1st Dec 20237:00 amRNSTotal Voting Rights
1st Nov 20238:55 amRNSTotal Voting Rights
26th Oct 20233:25 pmRNSDirector/PDMR Shareholding
28th Sep 20236:20 pmRNSHolding(s) in Company
14th Sep 202312:18 pmRNSDirector/PDMR Shareholding
12th Sep 20236:25 pmRNSFever-Tree FY23 Interim Results - Replacement
12th Sep 20237:00 amRNSFever-Tree FY23 Interim Results
1st Aug 20232:16 pmRNSTotal Voting Rights
3rd Jul 20234:00 pmRNSTotal Voting Rights
1st Jun 20237:00 amRNSBlock Listing Return
1st Jun 20237:00 amRNSTotal Voting Rights
25th May 20231:54 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.